It can invade ESCC cells and induce the NFκB pathway through the nucleotide-binding oligomerization domain-containing protein 1 (NOD1)/receptor interacting serine threonine kinase 2 (RIPK2) pathway, leading to tumor progression. The gene discussed is RIPK2; the disease is neoplasm.